Solute carrier family of the organic anion-transporting polypeptides 1A2- Madin-Darby canine kidney II: A promising in vitro system to understand the role of organic anion-transporting polypeptide 1a2 in blood-brain barrier drug penetration

Drug Metabolism and Disposition

Volumn 43, Issue 7, 2015, Pages 1008-1018

  Liu, Houfu ^a   Yu, Na ^a,f   Lu, Sijie ^a   Ito, Sumito ^c   Zhang, Xuan ^c   Prasad, Bhagwat ^e   He, Enuo ^b   Lu, Xinyan ^a   Li, Yang ^a   Wang, Fei ^a   Xu, Han ^a   An, Gang ^a   Unadkat, Jashvant D ^e   Kusuhara, Hiroyuki ^c   Sugiyama, Yuichi ^d   Sahi, Jasminder ^a  

^a GLAXOSMITHKLINE   (China)

^b GLAXOSMITHKLINE   (United Kingdom)

^c UNIVERSITY OF TOKYO   (Japan)

^d RIKEN   (Japan)

^e UNIVERSITY OF WASHINGTON   (United States)

^f NINGXIA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALMOTRIPTAN; FEXOFENADINE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; NARATRIPTAN; RIZATRIPTAN; ROSUVASTATIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1A2; SUMATRIPTAN; ZOLMITRIPTAN; DRUG; ORGANIC ANION TRANSPORTER; SLCO1A2 PROTEIN, HUMAN; TRYPTAMINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APICAL MEMBRANE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG LIVER LEVEL; DRUG PENETRATION; DRUG TRANSPORT; DRUG UPTAKE; HEK293 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MDCK CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPECIES DIFFERENCE; VIRAL GENE DELIVERY SYSTEM; WILD TYPE; ACTIVE TRANSPORT; ANIMAL; BIOLOGICAL MODEL; BIOSYNTHESIS; DOG; GENETICS; METABOLISM; TISSUE DISTRIBUTION;

MURINAE; MUS; RODENTIA;

ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; BLOOD-BRAIN BARRIER; DOGS; HEK293 CELLS; HUMANS; MADIN DARBY CANINE KIDNEY CELLS; MICE; MICE, KNOCKOUT; MODELS, BIOLOGICAL; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; PHARMACEUTICAL PREPARATIONS; ROSUVASTATIN CALCIUM; SPECIES SPECIFICITY; TISSUE DISTRIBUTION; TRYPTAMINES;

EID: 84940392265     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.115.064170     Document Type: Article

References (48)

1. Badagnani I, Castro RA, Taylor T.R., Brett CM, Huang CC, Stryke D, Kawamoto M., Johns SJ, Ferrin TE, and Carlson EJ, et al. (2006) Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther 318:521-529.
2. Bergström M., Yates R, Wall A., Kågedal M, Syvänen S, and Långström B (2006) Blood-brain barrier penetration of zolmitriptan - modelling of positron emission tomography data. J Pharmacokinet Pharmacodyn 33:75-91.
3. Bleasby K, Castle JC, Roberts C.J., Cheng C., Bailey WJ, Sina JF, Kulkarni AV, Hafey M.J., Evers R., and Johnson JM, et al. (2006) Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica 36:963-988.
4. Bourasset F, Cisternino S, Temsamani J., and Scherrmann JM (2003) Evidence for an active transport of morphine-6-beta-d-glucuronide but not P-glycoprotein-mediated at the blood-brain barrier. J Neurochem 86:1564-1567.
5. Bronger H, König J, Kopplow K., Steiner HH, Ahmadi R, Herold-Mende C, Keppler D, and Nies AT (2005) ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier. Cancer Res 65:11419-11428.
6. Cheng X, Maher J, Chen C., and Klaassen CD (2005) Tissue distribution and ontogeny of mouse organic anion transporting polypeptides (Oatps). Drug Metab Dispos 33:1062-1073.
7. Cheng Z, Liu H, Yu N., Wang F, An G, Xu Y., Liu Q, Guan CB, and Ayrton A (2012) Hydrophilic anti-migraine triptans are substrates for OATP1A2, a transporter expressed at human blood-brain barrier. Xenobiotica 42:880-890.
8. Ciurleo R, Bramanti P, and Marino S (2014) Role of statins in the treatment of multiple sclerosis. Pharmacol Res 87:133-143.
9. Cvetkovic M, Leake B, Fromm M.F., Wilkinson GR, and Kim RB (1999) OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866-871.
10. Dixon CM, Saynor DA, Andrew P.D., Oxford J., Bradbury A, and Tarbit MH (1993) Disposition of sumatriptan in laboratory animals and humans. Drug Metab Dispos 21:761-769.
11. Drozdzik M, Gröer C, Penski J., Lapczuk J, Ostrowski M, Lai Y., Prasad B, Unadkat JD, Siegmund W, and Oswald S (2014) Protein abundance of clinically relevant multidrug transporters along the entire length of the human intestine. Mol Pharm 11:3547-3555.
12. Eechoute K, Franke RM, Loos W.J., Scherkenbach LA, Boere I, Verweij J, Gurney H., Kim RB, Tirona RG, and Mathijssen RH, et al. (2011) Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther 89:816-820.
13. Evans DC, O'Connor D, Lake BG, Evers R, Allen C., and Hargreaves R (2003) Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab Dispos 31:861-869.
14. Feng B, Mills JB, Davidson R.E., Mireles RJ, Janiszewski JS, Troutman MD, and de Morais SM (2008) In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos 36:268-275.
15. Fonfara S, Hetzel U, Tew S.R., Dukes-McEwan J, Cripps P, and Clegg PD (2011) Leptin expression in dogs with cardiac disease and congestive heart failure. J Vet Intern Med 25: 1017-1024.
16. Franke RM, Scherkenbach LA, and Sparreboom A (2009) Pharmacogenetics of the organic anion transporting polypeptide 1A2. Pharmacogenomics 10:339-344.
17. Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D., Aguzzi A, and Meier PJ (2000) Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J Pharmacol Exp Ther 294:73-79.
18. Gao B, Stieger B, Noé B, Fritschy JM, and Meier PJ (1999) Localization of the organic anion transporting polypeptide 2 (Oatp2) in capillary endothelium and choroid plexus epithelium of rat brain. J Histochem Cytochem 47:1255-1264.
19. Gao B, Vavricka SR, Meier P.J., and Stieger B (2014) Differential cellular expression of organic anion transporting peptides OATP1A2 and OATP2B1 in the human retina and brain: implications for carrier-mediated transport of neuropeptides and neurosteriods in the CNS. Pflugers Arch DOI: 10.1007/s00424-014-1596-x [published ahead of print].
20. Glaeser H, Bailey DG, Dresser G.K., Gregor JC, Schwarz UI, McGrath JS, Jolicoeur E, Lee W., Leake BF, and Tirona RG, et al. (2007) Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther 81:362-370.
21. Hagenbuch B, Gao B, and Meier PJ (2002) Transport of xenobiotics across the blood-brain barrier. News Physiol Sci 17:231-234.
22. Horibe S, Nagai J, Yumoto R., Tawa R, and Takano M (2011) Accumulation and photodynamic activity of chlorin e6 in cisplatin-resistant human lung cancer cells. J Pharm Sci 100: 3010-3017.
23. Hsiao P and Unadkat JD (2014) Predicting the outer boundaries of P-glycoprotein (P-gp)-based drug interactions at the human blood-brain barrier based on rat studies. Mol Pharm 11: 436-444.
24. Huang L, Wang Y, and Grimm S (2006) ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. Drug Metab Dispos 34:738-742.
25. Humphrey PP, Feniuk W, Perren M.J., Beresford IJ, Skingle M, and Whalley ET (1990) Serotonin and migraine. Ann N Y Acad Sci 600:587-598, discussion 598-600
26. Kalvass JC, Polli JW, Bourdet D.L., Feng B., Huang SM, Liu X, Smith QR, Zhang L.K., and Zamek-Gliszczynski MJ; International Transporter Consortium (2013) Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position. Clin Pharmacol Ther 94:80-94.
27. Kamiie J, Ohtsuki S, Iwase R., Ohmine K, Katsukura Y, Yanai K., Sekine Y, Uchida Y, Ito S., and Terasaki T (2008) Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. Pharm Res 25:1469-1483.
28. Kikuchi R, Kusuhara H, Abe T., Endou H, and Sugiyama Y (2004) Involvement of multiple transporters in the efflux of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors across the blood-brain barrier. J Pharmacol Exp Ther 311:1147-1153.
29. Kullak-Ublick G.A., Hagenbuch B, Stieger B., Schteingart CD, Hofmann AF, Wolkoff AW, and Meier PJ (1995) Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology 109:1274-1282.
30. Kuteykin-Teplyakov K., Luna-Tortós C, Ambroziak K, and Löscher W (2010) Differences in the expression of endogenous efflux transporters in MDR1-transfected versus wildtype cell lines affect P-glycoprotein mediated drug transport. Br J Pharmacol 160:1453-1463.
31. Lee W, Glaeser H, Smith L.H., Roberts RL, Moeckel GW, Gervasini G, Leake B.F., and Kim RB (2005) Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J Biol Chem 280:9610-9617.
32. Liu H, Li Y, Lu S., Wu Y, and Sahi J (2014) Temporal expression of transporters and receptors in a rat primary co-culture blood-brain barrier model. Xenobiotica 44:941-951.
33. Maeda T, Takahashi K, Ohtsu N., Oguma T, Ohnishi T, Atsumi R., and Tamai I (2007) Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm 4: 85-94.
34. Maubon N, Le Vee M, Fossati L, Audry M., Le Ferrec E, Bolze S, and Fardel O (2007) Analysis of drug transporter expression in human intestinal Caco-2 cells by real-time PCR. Fundam Clin Pharmacol 21:659-663.
35. Mayerl S, Visser TJ, Darras V.M., Horn S., and Heuer H (2012) Impact of Oatp1c1 deficiency on thyroid hormone metabolism and action in the mouse brain. Endocrinology 153:1528-1537.
36. Ose A, Kusuhara H, Endo C., Tohyama K, Miyajima M, Kitamura S., and Sugiyama Y (2010) Functional characterization of mouse organic anion transporting peptide 1a4 in the uptake and efflux of drugs across the blood-brain barrier. Drug Metab Dispos 38:168-176.
37. Prasad B, Evers R, Gupta A., Hop CE, Salphati L, Shukla S, Ambudkar S.V., and Unadkat JD (2014) Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex. Drug Metab Dispos 42:78-88.
38. Rautio J, Humphreys JE, Webster L.O., Balakrishnan A., Keogh JP, Kunta JR, Serabjit-Singh CJ, and Polli JW (2006) In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos 34:786-792.
39. Ronaldson PT, Finch JD, Demarco K.M., Quigley CE, and Davis TP (2011) Inflammatory pain signals an increase in functional expression of organic anion transporting polypeptide 1a4 at the blood-brain barrier. J Pharmacol Exp Ther 336:827-839.
40. Sakai Y, Dobson C, Diksic M., Aubé M, and Hamel E (2008) Sumatriptan normalizes the migraine attack-related increase in brain serotonin synthesis. Neurology 70:431-439.
41. Sierra S, Ramos MC, Molina P, Esteo C., Vázquez JA, and Burgos JS (2011) Statins as neuro-protectants: a comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. J Alzheimers Dis 23:307-318.
42. Taogoshi T, Nomura A, Murakami T., Nagai J, and Takano M (2005) Transport of prostaglandin E1 across the blood-brain barrier in rats. J Pharm Pharmacol 57:61-66.
43. Tran TT, Mittal A, Gales T., Maleeff B, Aldinger T, Polli J.W., Ayrton A., Ellens H, and Bentz J (2004) Exact kinetic analysis of passive transport across a polarized confluent MDCK cell monolayer modeled as a single barrier. J Pharm Sci 93:2108-2123.
44. Uchida Y, Ohtsuki S, Kamiie J., and Terasaki T (2011a) Blood-brain barrier (BBB) pharmaco-proteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice. J Pharmacol Exp Ther 339:579-588.
45. Uchida Y, Ohtsuki S, Katsukura Y., Ikeda C, Suzuki T, Kamiie J., and Terasaki T (2011b) Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J Neurochem 117:333-345.
46. Uchida Y, Wakayama K, Ohtsuki S., Chiba M, Ohe T, Ishii Y., and Terasaki T (2014) Blood-brain barrier pharmacoproteomics-based reconstruction of the in vivo brain distribution of P-glycoprotein substrates in cynomolgus monkeys. J Pharmacol Exp Ther 350:578-588.
47. Urquhart BL and Kim RB (2009) Blood-brain barrier transporters and response to CNS-active drugs. Eur J Clin Pharmacol 65:1063-1070.
48. Wang J, Guo LP, Chen L.Z., Zeng YX, and Lu SH (2007) Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res 67:3716-3724.